从中美社会角度评价索托拉西与多西他赛治疗KRASG12C突变非小细胞肺癌（NSCLC）患者的成本效果。马尔可夫模型包含三种状态（无进展生存期、进展后生存期）生存和死亡）被开发出来。计算两种治疗策略的增量成本效益比 (ICER)、质量调整生命年 (QALY) 和增量 QALY。采用单向敏感性分析来考察对模型结果影响较大的因素，并采用龙卷风图来呈现结果。通过 1,000 次蒙特卡洛模拟进行概率敏感性分析。根据参数类型假设分布，并每次对所有参数分布进行随机抽样。结果以成本效益可接受的曲线形式呈现。此经济评估数据来自 CodeBreak 200 随机临床试验。在中国，sotorasib 产生了 0.44 QAYL，总成本为 84372.59 美元。与多西紫杉醇相比，sotorasib的ICER值为102701.84美元/QALY，高于支付意愿（WTP），因此sotorasib不具有经济优势。在美国，sotorasib比多西他赛多获得了0.35 QALY，ICER为15,976.50美元/QALY，超过1个WTP但低于3个WTP，表明sotorasib增加的成本是可以接受的。单因素敏感性分析显示，随着中国随访检查费用的降低，sotorasib产生经济效益的概率逐渐增加。在中国的变化范围内，对结论没有影响。当支付意愿（WTP）超过102,500美元时，Sotorasib产生成本效应的概率从0%增加到49%。从美国的角度来看，Sotorasib具有成本效应。然而，从中国的角度来看，sotorasib 不存在成本效应，只有当支付意愿超过 102,500 美元时，sotorasib 产生成本效应的概率从 0% 增加到 49%。版权所有 © 2024 Zhu, Tang, Sun, Gau, Shi and Zhang 。

To evaluate the cost-effectiveness of sotorasib versus docetaxel in non-small cell lung cancer (NSCLC) patients with KRASG12C mutation from the China and United States'social perspective.A Markov model that included three states (progression-free survival, post-progression survival, and death) was developed. Incremental cost-effectiveness ratio (ICER), quality-adjusted life-year (QALY), and incremental QALY were calculated for the two treatment strategies. One-way sensitivity analysis was used to investigate the factors that had a greater impact on the model results, and tornado diagrams were used to present the results. Probabilistic sensitivity analysis was performed with 1,000 Monte Carlo simulations. Assume distributions based on parameter types and randomly sample all parameter distributions each time., The results were presented as cost-effectiveness acceptable curves.This economic evaluation of data from the CodeBreak 200 randomized clinical trial. In China, sotorasib generated 0.44 QAYL with a total cost of $84372.59. Compared with docetaxel, the ICER value of sotorasib was $102701.84/QALY, which was higher than willingness to pay (WTP), so sotorasib had no economic advantage. In the US, sotorasib obtained 0.35 QALY more than docetaxel, ICER was $15,976.50/QALY, which was more than 1 WTP but less than 3 WTP, indicating that the increased cost of sotorasib was acceptable. One-way sensitivity analysis showed that the probability of sotorasib having economic benefits gradually increased when the cost of follow-up examination was reduced in China. And there was no influence on the conclusions within the range of changes in China. When the willingness to pay (WTP) exceeds $102,500, the probability of sotorasib having cost effect increases from 0% to 49%.Sotorasib had a cost effect from the perspective in the United States. However, sotorasib had no cost effect from the perspective in China, and only when the WTP exceeds $102,500, the probability of sotorasib having cost effect increases from 0% to 49%.Copyright © 2024 Zhu, Tang, Sun, Gao, Shi and Zhang.